Claudia Blais1, Sulan Dai2, Chris Waters3, Cynthia Robitaille3, Mark Smith4, Lawrence W Svenson5, Kim Reimer6, Jill Casey7, Rolf Puchtinger8, Helen Johansen9, Yana Gurevich10, Lisa M Lix11, Hude Quan12, Karen Tu13. 1. Institut national de santé publique du Québec, Québec City, Québec, Canada; Faculté de pharmacie, Université Laval, Québec City, Québec, Canada. 2. Centre for Chronic Disease Prevention, Public Health Agency of Canada, Ottawa, Ontario, Canada. Electronic address: sulan.dai@phac-aspc.gc.ca. 3. Centre for Chronic Disease Prevention, Public Health Agency of Canada, Ottawa, Ontario, Canada. 4. Manitoba Centre for Health Policy, Winnipeg, Manitoba, Canada. 5. Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada; Alberta Health, Edmonton, Alberta, Canada; School of Public Health, University of Alberta, Edmonton, Alberta, Canada. 6. BC Ministry of Health, Victoria, British Columbia, Canada. 7. Nova Scotia Health and Wellness, Halifax, Nova Scotia, Canada. 8. Saskatchewan Ministry of Health, Regina, Saskatchewan, Canada. 9. Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada. 10. Canadian Institute for Health Information, Toronto, Ontario, Canada. 11. University of Manitoba, Winnipeg, Manitoba, Canada. 12. Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada. 13. Institute for Clinical Evaluative Sciences; Department of Family and Community Medicine, University of Toronto; University Health Network, Toronto Western Hospital Family Health Team, Toronto, Ontario, Canada.
Abstract
BACKGROUND: The surveillance of heart failure (HF) is currently conducted using either survey or hospital data, which have many limitations. Because Canada is collecting medical information in administrative health data, the present study seeks to propose methods for the national surveillance of HF using linked population-based data. METHODS: Linked administrative data from 5 Canadian provinces were analyzed to estimate prevalence, incidence, and mortality rates for persons with HF between 1996/1997 and 2008/2009 using 2 case definitions: (1) 1 hospitalization with an HF diagnosis in any field (H_Any) and (2) 1 hospitalization in any field or at least 2 physician claims within a 1-year period (H_Any_2P). One hospitalization with an HF diagnosis code in the most responsible diagnosis field (H_MR) was also compared. Rates were calculated for individuals aged ≥ 40 years. RESULTS: In 2008/2009, combining the 5 provinces (approximately 82% of Canada's total population), both age-standardized HF prevalence and incidence were underestimated by 39% and 33%, respectively, with H_Any when compared with H_Any_2P. Mortality was higher in patients with H_MR compared with H_Any. The degree of underestimation varied by province and by age, with older age groups presenting the largest differences. Prevalence estimates were stable over the years, especially for the H_Any_2P case definition. CONCLUSIONS: The prevalence and incidence of HF using inpatient data alone likely underestimates the population rates by at least 33%. The addition of physician claims data is likely to provide a more inclusive estimate of the burden of HF in Canada. Crown
BACKGROUND: The surveillance of heart failure (HF) is currently conducted using either survey or hospital data, which have many limitations. Because Canada is collecting medical information in administrative health data, the present study seeks to propose methods for the national surveillance of HF using linked population-based data. METHODS: Linked administrative data from 5 Canadian provinces were analyzed to estimate prevalence, incidence, and mortality rates for persons with HF between 1996/1997 and 2008/2009 using 2 case definitions: (1) 1 hospitalization with an HF diagnosis in any field (H_Any) and (2) 1 hospitalization in any field or at least 2 physician claims within a 1-year period (H_Any_2P). One hospitalization with an HF diagnosis code in the most responsible diagnosis field (H_MR) was also compared. Rates were calculated for individuals aged ≥ 40 years. RESULTS: In 2008/2009, combining the 5 provinces (approximately 82% of Canada's total population), both age-standardized HF prevalence and incidence were underestimated by 39% and 33%, respectively, with H_Any when compared with H_Any_2P. Mortality was higher in patients with H_MR compared with H_Any. The degree of underestimation varied by province and by age, with older age groups presenting the largest differences. Prevalence estimates were stable over the years, especially for the H_Any_2P case definition. CONCLUSIONS: The prevalence and incidence of HF using inpatient data alone likely underestimates the population rates by at least 33%. The addition of physician claims data is likely to provide a more inclusive estimate of the burden of HF in Canada. Crown
Authors: Ricky Camplain; Anna Kucharska-Newton; Carmen C Cuthbertson; Jacqueline D Wright; Alvaro Alonso; Gerardo Heiss Journal: Pharmacoepidemiol Drug Saf Date: 2017-01-25 Impact factor: 2.890
Authors: Ashlay A Huitema; Alexia Daoust; Kim Anderson; Stephanie Poon; Sean Virani; Michel White; Carlos Rojas-Fernandez; Shelley Zieroth; Robert S McKelvie Journal: CJC Open Date: 2020-04-05
Authors: Morgan Slater; Joanna Bielecki; Ana Carolina Alba; Lusine Abrahamyan; George Tomlinson; Susanna Mak; Jane MacIver; Shelley Zieroth; Douglas Lee; William Wong; Murray Krahn; Heather Ross; Valeria E Rac Journal: Syst Rev Date: 2019-02-02
Authors: Lisa M Lix; James Ayles; Sharon Bartholomew; Charmaine A Cooke; Joellyn Ellison; Valerie Emond; Naomi C Hamm; Heather Hannah; Sonia Jean; Shannon LeBlanc; Siobhan O'Donnell; J Michael Paterson; Catherine Pelletier; Karen A M Phillips; Rolf Puchtinger; Kim Reimer; Cynthia Robitaille; Mark Smith; Lawrence W Svenson; Karen Tu; Linda D VanTil; Sean Waits; Louise Pelletier Journal: Int J Popul Data Sci Date: 2018-10-05